An attractive pipeline leveraging the technology


XON7 is a multispecific antibody issued from the GH-pAb platform by XENOTHERA. It targets several solid tumors including major cancers where the unmet medical need is important, namely lung, prostate, ovarian, pancreas. XON7 targets several tumoral antigens. Its biological activity is based on its specific mechanisms of action, namely CDC, apoptosis, ADCP and immunity induction. XON7 is in clinic since 2023.


LIS22 is addressing the major unmet medical need of T cell lymphoma. It targets several markers of T lymphomas and binds to up to 90% of patient tumoral cells. Peripheral T cell lymphomas are a class of non-hodgkin lymphomas with pejorative prognosis. LIS22 is a hope for patients for whom there is no treatment currently available. An orphan drug designation has been granted to the product by the FDA in 2023. The phase II clinical trial application is under review by EMA.

XON 5 & XON 9

XON5 and XON9 are other anti-tumoral GH-pAbs which target solid tumors different from XON7, through a different set of tumoral antigens. These two antibodies have finalized preclinical data.


LIS1 is our program in solid organ transplantation. LIS1 is a GH-pAb that acts a soft depleting induction agent in solid organ transplantation. It deplete CD4 and CD8 lymphocytes with optimized recovery, and spares other cells. It acts through depletion and inhibition of alloreactivity. As such, it is an exciting candidate to replace current induction treatments which face side effects or limited efficacy. LIS1 has been granted orphan drug designation by FDA (2020) and EMA (2022). The completion of the phase I/II clinical trial in 2022 has confirmed the interest of this innovative induction treatment in solid organ transplantation.

XAV03, XAB05, XAB06, and XAV19

XAV03, XAB05, XAB06, and XAV19 are the different GH-pAb developed in infectious diseases. The anti-bacteria XAB05 and XAB06 are respectively at phase I and preclinical stage. The anti-SARS-Cov2 GH-pAb named XAV19 has demonstrated its capacity to maintain its biological activity against all variants of concern and its clinical efficacy in early-stage mild to moderate COVID19.